390 related articles for article (PubMed ID: 20404132)
1. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
2. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
[TBL] [Abstract][Full Text] [Related]
3. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
[TBL] [Abstract][Full Text] [Related]
4. When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.
Oh ST
Ther Adv Hematol; 2011 Feb; 2(1):11-9. PubMed ID: 23556072
[TBL] [Abstract][Full Text] [Related]
5. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
6. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
7. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
8. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
[TBL] [Abstract][Full Text] [Related]
9. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.
Tong W; Lodish HF
J Exp Med; 2004 Sep; 200(5):569-80. PubMed ID: 15337790
[TBL] [Abstract][Full Text] [Related]
10. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
11. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract][Full Text] [Related]
12. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
Gery S; Cao Q; Gueller S; Xing H; Tefferi A; Koeffler HP
J Leukoc Biol; 2009 Jun; 85(6):957-65. PubMed ID: 19293402
[TBL] [Abstract][Full Text] [Related]
13. Role of the adaptor protein LNK in normal and malignant hematopoiesis.
Gery S; Koeffler HP
Oncogene; 2013 Jun; 32(26):3111-8. PubMed ID: 23045270
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
[TBL] [Abstract][Full Text] [Related]
15. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
[TBL] [Abstract][Full Text] [Related]
16. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
[TBL] [Abstract][Full Text] [Related]
17. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms.
Sakr H; Clark Schneider K; Murugesan G; Bodo J; Hsi ED; Cook JR
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):147-152. PubMed ID: 27258562
[TBL] [Abstract][Full Text] [Related]
18. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
19. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
[TBL] [Abstract][Full Text] [Related]
20. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
